MedTrace Logo

Electroporation Potentiated Immunotherapy in Cancer

NCT04835402 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-03-09

No results posted yet for this study

Summary

The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.

Conditions

  • Pancreas Cancer, Metastatic

Interventions

DRUG

Pembrolizumab

400mg every 6 weeks

DEVICE

Irreversible electroporation

Percutaneous ablation of one liver metastasis

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Aalborg University

    collaborator OTHER

  • Danish Cancer Society

    collaborator OTHER

  • Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery

    lead OTHER

Principal Investigators

  • Morten Ladekarl, DMSc · Department of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-26
Primary Completion
2022-03-07
Completion
2025-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835402 on ClinicalTrials.gov